Maribavir (Livtencity)

CADTH recommends that Livtencity should be reimbursed by public drug plans for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to 1 or more prior antiviral therapies if certain conditions are met. Livtencity should only be covered to treat adult patients with CMV infections that are refractory (with or without resistance) to 1 or more of the following antiviral drugs: valganciclovir, ganciclovir, foscarnet, or cidofovir. Livtencity should only be reimbursed if prescribed by clinicians with experience and expertise in transplant medicine, transplant infectious disease, or infectious diseases, and if the cost of Livtencity is reduced.